Welcome to visit Zhongnan Medical Journal Press Series journal website!

Home Articles Vol 27,2024 No.5 Detail

Clinical efficacy of butylphthalide sequential therapy combined with hyperbaric oxygen therapy and glucocorticoid in patients with delayed encephalopathy of acute carbon monoxide poisoning

Published on May. 31, 2024Total Views: 79 times Total Downloads: 170 times Download Mobile

Author: HAO Meimei 1 TIAN Tian 1 BAI Ruyu 1 BAN Yuxia 1 KANG Jing 2

Affiliation: 1. Department of Neurology, Yan'an People's Hospital, Yanan 716000, Shaanxi Province, China 2. Department of Brain Disease, Yan'an Traditional Chinese Medicine Hospital, Yanan 716000, Shaanxi Province, China

Keywords: Delayed encephalopathy of acute carbon monoxide poisoning Butylphthalide sequential therapy Clinical efficacy Hyperbaric oxygenation Glucocorticoids Clinical efficacy

DOI: 10.12173/j.issn.1008-049X.202403140

Reference: HAO Meimei, TIAN Tian, BAI Ruyu, BAN Yuxia, KANG Jing.Clinical efficacy of butylphthalide sequential therapy combined with hyperbaric oxygen therapy and glucocorticoid in patients with delayed encephalopathy of acute carbon monoxide poisoning[J].Zhongguo Yaoshi Zazhi,2024, 24(5):817-825.DOI: 10.12173/j.issn.1008-049X.202403140.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective  To assess the clinical efficacy of butylphthalide sequential therapy (BST) as an adjuvant therapy for delayed onset encephalopathy caused by acute carbon monoxide poisoning (DEACMP).

Methods  DEACMP patients who visited the department of neurology at Yan'an People's Hospital from January 2018 to June 2023 were selected as the research subjects. Using a random number table method, DEACMP patients were randomly divided into hyperbaric oxygen therapy (HBOT) group, glucocorticoid (GC) group (GC combined with, HBOT), and BST group (HBOT, GC combined with BST), all of which were treated continuously for 30 days. The incidence of adverse reactions and clinical efficacy during the  treatment among three groups of DEACMP were observed and compared. Inflammation indicators, neurological damage indicators, cognitive function, neurological function, and daily living ability before and after treatment among three groups were compared.

Results  A total of 120 patients were included in the study, with 40 patients in each group. During the treatment period, no serious adverse reactions were observed in any of the three groups of patients, and no patient terminated treatment due to adverse reactions. The total effective rate of BST group was significantly higher than those of GC group and HBOT group, while the total effective rate of GC group was higher than that of HBOT group (P<0.05). Before treatment, there was no statistically significant difference (P>0.05) in the scores of inflammation indicators, neurological damage indicators, cognitive function, neurological function, and daily living function among the three groups. After treatment, the serum LP-PLA2, SIRI, TNF-α, S100- β, and the NSE levels decreased compared to before treatment (P<0.05), and the indicators of the BST group was lower than those of the HBOT group and GC group, while the indicators of the GC group was lower than those of the HBOT group (P<0.05). After treatment, the MMSE, MoCA, and BI scores of the three groups increased compared to before treatment (P<0.05), but the NIHSS score decreased (P<0.05). In addition, the MMSE, MoCA, and BI scores of the BST group were higher than those of the HBOT and GC groups (P<0.05), while the NIHSS scores were lower than those of the HBOT and GC groups (P<0.05). The MMSE, MoCA, and BI scores in the GC group were higher than those in the HBOT group, while the NIHSS scores were lower than those in the HBOT group (P<0.05).

Conclusion  Compared with HBOT treatment and HBOT combined with GC treatment, BST adjuvant therapy can improve the clinical efficacy, inflammatory status, cognitive function, and daily living ability of DECAMP patients.

Full-text
Please download the PDF version to read the full text: download
References

1.黄文彬, 刘伟, 夏梦梅, 等. 急性一氧化碳中毒迟发性脑病列线图预测模型的构建[J]. 华西医学, 2023, 38(11): 1648-1654. [Huang WB, Liu W, Xia MM, et al. Construction of a column chart prediction model for delayed encephalopathy caused by acute carbon monoxide poisoning [J]. West China Medical Journal, 2023, 38 (11): 1648-1654.] DOI: 10.7507/1002-0179.202310019.

2.Rose JJ, Wang L, Xu Q, et al. Carbon monoxide poisoning: pathogenesis, management, and future directions of therapy[J]. Am J Respir Crit Care Med, 2017, 195(5): 596-606. DOI: 10.1164/rccm.201606-1275CI.

3.Huang F, Yang L, Tan Z, et al. Prognostic factors of hyperbaric oxygen therapy for patients with delayed encephalopathy after acute carbon monoxide poisoning[J]. Heliyon, 2022, 8(12): e12351. DOI: 10.1016/j.heliyon. 2022.e12351.

4.Huang YQ, Peng ZR, Huang FL, et al. Mechanism of delayed encephalopathy after acute carbon monoxide poisoning[J]. Neural Regen Res, 2020, 15(12): 2286-2295. DOI: 10.4103/1673-5374.284995.

5.王东青, 孟艳婕, 陈懋, 等. 胞磷胆碱辅助高压氧治疗CO中毒致急性脑缺氧患者疗效[J]. 西部医学, 2023, 35(4): 558-562. [Wang DQ, Meng YJ, Chen M, et al. The efficacy of cytidine assisted hyperbaric oxygen therapy in the treatment of acute cerebral hypoxia caused by CO poisoning[J]. Western Medicine, 2023, 35(4): 558-562.] DOI: 10.3969/j.issn.1672-3511.2023.04.018.

6.任玲, 何成奇. 高压氧治疗改善认知功能障碍的研究进展[J]. 华西医学, 2023, 38(4): 597-602. [Ren L, He CQ. Research progress on improving cognitive impairment with hyperbaric oxygen therapy [J]. Huaxi Medical Journal, 2023,38 (4): 597-602.] DOI: 10.7507/1002-0179.202203129.

7.金开林, 赵琴, 黄应亮. 鼓室注射糖皮质激素和高压氧治疗对特发性突发性感音神经性耳聋的疗效 [J]. 中国药师, 2024, 27(2): 302-308. [Jin KL, Zhao Q, Huang YL. The therapeutic effect of tympanic injection of glucocorticoids and hyperbaric oxygen therapy on idiopathic sudden sensorineural hearing loss[J]. Chinese Pharmacologist, 2024, 27(2): 302-308.] DOI: 10.12173/j.issn.1008-049X.202312105.

8.Hentia C, Rizzato A, Camporesi E, et al. An overview of protective strategies against ischemia/reperfusion injury: The role of hyperbaric oxygen preconditioning[J]. Brain Behav, 2018, 8(5): e00959. DOI: 10.1002/brb3.959.

9.Oyaizu T, Enomoto M, Yamamoto N, et al. Hyperbaric oxygen reduces inflammation, oxygenates injured muscle, and regenerates skeletal muscle via macrophage and satellite cell activation[J]. Sci Rep, 2018, 8(1): 1288. DOI: 10.1038/s41598-018-19670-x.

10.Wang SD, Fu YY, Han XY, et al. Hyperbaric oxygen preconditioning protects against cerebral ischemia/reperfusion injury by inhibiting mitochondrial apoptosis and energy metabolism disturbance[J]. Neurochem Res, 2021, 46(4): 866-877. DOI: 10.1007/s11064-020-03219 -4.

11.Hu H, Pan X, Wan Y, et al. Factors affecting the prognosis of patients with delayed encephalopathy after acute carbon monoxide poisoning[J]. Am J Emerg Med, 2011, 29(3): 261-264. DOI: 10.1016/j.ajem.2009.09.030.

12.Xu XM, Luo H, Rong BB, et al. Management of delayed encephalopathy after CO poisoning: an evidence-based narrative review[J]. Medicine, 2019, 98(49): e18199. DOI: 10.1097/MD.0000000000018199.

13.Liu J, Si Z, Liu J, et al. Clinical and imaging prognosis in patients with delayed encephalopathy after acute carbon monoxide poisoning[J]. Behav Neurol, 2020, 2020: 1719360. DOI: 10.1155/2020/1719360.

14.王娜, 许铁, 胡书群, 等. 高压氧联合糖皮质激素治疗急性一氧化碳中毒迟发性脑病的Meta分析[J]. 中国急救复苏与灾害医学杂志, 2023, 18(5): 617-624, 673. [Wang N, Xu T, Hu SQ, et al. Meta-analysis of hyperbaric oxygen combined with glucocorticoids in the treatment of delayed encephalopathy after acute carbon monoxide poisoning[J]. Chinese Journal of Emergency Resuscitation and Disaster Medicine, 2023, 18(5): 617-624, 673.] DOI: 10.3969/j.issn.1673-6966.2023.05.013.

15.唐庆, 李颖, 王永义, 等. 糖皮质激素联合高压氧防治急性一氧化碳中毒迟发性脑病疗效与安全性Meta分析[J]. 第三军医大学学报, 2016, 38(2): 207-214. [Tang Q, Li Y, Wang YY, et al. Meta-analysis of the efficacy and safety of glucocorticoids combined with hyperbaric oxygen in the prevention and treatment of delayed encephalopathy after acute carbon monoxide poisoning[J]. Journal of Third Military Medical University, 2016, 38(2): 207-214.] DOI: 10.16016/j.1000-5404.201510064.

16.Wang S, Ma F, Huang L, et al. Dl-3-n-butylphthalide (NBP): a promising therapeutic agent for ischemic stroke[J]. CNS Neurol Disord Drug Targets, 2018, 17(5): 338-347. DOI: 10.2174/1871527317666180612125843.

17.陈艳坤, 李慧, 吴延芝, 等. 丁苯酞对迟发性脑病患者精神、行为和认知的影响[J]. 中国现代医生, 2022, 60(5): 22-25. [Chen YK, Li H, Wu YZ, et al. The influence of butylphthalide on the mental, behavioral, and cognitive aspects of patients with delayed encephalopathy[J]. Chinese Modern Doctors, 2022, 60(5): 22-25.] https://xueshu.baidu.com/usercenter/paper/show?paperid=17260md0ug6e0vx0jr7e00t0uj543933&site=xueshu_se&hitarticle=1.

18.李秀娟, 周景芬. 丁苯酞联合高压氧对一氧化碳中毒迟发性脑病患者神经功能的影响[J]. 中国老年学杂志, 2017, 37(23): 5926-5928. [Li XJ, Zhou JF. The effect of butylphthalide combined with hyperbaric oxygen on neurological function in patients with delayed encephalopathy after carbon monoxide poisoning[J]. Chinese Journal of Gerontology, 2017, 37(23): 5926-5928.] DOI: 10.3969/j. issn.1005-9202.2017.23.083.

19.王建国. 丁苯酞序贯疗法在急性脑梗死合并认知功能障碍治疗中的临床应用[J]. 吉林医学, 2020, 41(9): 2166-2167. [Wang JG. The clinical application of sequential therapy with butylphthalide in the treatment of acute cerebral infarction complicated with cognitive dysfunction[J]. Jilin Medicine, 2020, 41(9): 2166-2167.] DOI: 10.3969/j.issn.1004-0412.2020.09.048.

20.谭月娥, 李宝丽, 王耀萱, 等. 丁苯酞序贯疗法治疗急性脑梗死临床疗效的Meta分析[J]. 中华脑血管病杂志(电子版) , 2020, 14(6): 352-358. [Tan YE, Li BL, Wang YX, et al. Meta analysis of the clinical efficacy of sequential therapy with butylphthalide in the treatment of acute cerebral infarction[J]. Chinese Journal of Cerebrovascular Disease(Electronic Edition), 2020, 14(6): 352-358. ] DOI: 10.11817/j. issn.1673-9248.2020.06.007.

21.甘依平. 丁苯酞治疗一氧化碳中毒迟发性脑病的有效性与安全性: 一项多中心、随机对照临床研究 [D]. 呼和浩特: 内蒙古医科大学, 2022.

22.朱红灿, 岳培建. CO中毒迟发性脑病诊断与治疗中国专家共识[J]. 中国神经免疫学和神经病学杂志, 2021, 28(3): 173-179. [Zhu HC, Yue PJ. Chinese experts consensus on diagnosis and treatment of delayed encephalopathy after CO poisoning[J]. Chinese Journal of Neuroimmunology and Neurology, 2021, 28(3): 173-179.] DOI: 10.3969/j.issn.1006-2963.2021.03.001.

23.Jia X, Wang Z, Huang F, et al. A comparison of the Mini-mental state examination (MMSE) with the montreal cognitive assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study[J]. BMC psychiatry, 2021, 21(1): 485. DOI: 10.1186/s12888-021-03495-6.

24.侯东哲, 张颖, 巫嘉陵, 等. 中文版美国国立卫生院脑卒中量表的信度与效度研究[J]. 中华物理医学与康复杂志, 2012(5): 372-374. [Hou DZ, Zhang Y, Wu JL, et al. Study on the reliability and validity of the Chinese version of the National Institutes of Health Stroke Scale[J]. Chinese Journal of Physical Medicine and Rehabilitation, 2012(5): 372-374.] DOI: 10.3760/cma.j.issn.0254-1424. 2012. 05.013.

25.侯东哲, 张颖, 巫嘉陵, 等. 中文版Barthel指数的信度与效度研究[J]. 临床荟萃, 2012, 27(3):219-221.[Hou DZ, Zhang Y, Wu JL, et al. Research on the reliability and validity of the Chinese version of barthel index[J]. Clinical Metastasis, 2012, 27(3): 219-221.] DOI: 10.3760/cma.j.issn.0254-1424.2012.05.013.

26.石雨, 王宝军, 陈超. 一氧化碳中毒迟发性脑病机制的研究进展[J]. 中国医药, 2023, 18(6): 940-944. [Shi Y, Wang BJ, Chen C. Progress in the study of the mechanism of delayed encephalopathy after carbon monoxide poisoning[J]. Chinese Medicine, 2023, 18(6): 940-944.] DOI: 10.3760/j. issn.1673-4777.2023.06.032.

27.牛翻燕, 项文平, 薛慧, 等. 星形胶质细胞及其炎症因子在CO中毒所致迟发性脑损伤中的作用[J]. 脑与神经疾病杂志, 2022, 30(11): 665-670. [Niu FY, Xiang WP, Xue H, et al. The role of astrocytes and their inflammatory factors in delayed brain injury caused by CO poisoning[J]. Journal of Brain and Nervous Disease, 2022, 30(11): 665-670.] https://xueshu.baidu.com/usercenter/paper/show?paperid=1q0a08m0nh0t0x80151u0v10g3093774&site=xueshu_se&hitarticle=1.

28.Qiao S, Li H, Guo F, et al. Research progress on cognitive impairment and the expression of serum inflammatory markers in patients with white matter hyperintensities: a narrative review[J]. Ann Transl Med, 2022, 10(7): 421. DOI: 10.21037/atm-22-1016.

29.Wang X, Li T, Li H, et al. Association of dietary inflammatory potential with blood inflammation: the prospective markers on mild cognitive impairment[J]. Nutrients, 2022, 14(12): 2417. DOI: 10.3390/nu14122417.

30.邓云飞, 李惠红, 魏伟, 等. 泽泻醇A保护血脑屏障改善脑缺血/再灌注损伤的作用和机制研究[J]. 中国药理学通报, 2024, 40(1): 83-90. [Deng YF, Li HH, Wei W, et al. The protective effect and mechanism of alisol A on blood-brain barrier injury during cerebral ischemia/reperfusion[J]. Chinese Pharmacological Bulletin, 2024, 40(1): 83-90.] DOI: 10.12360/CPB202305018.

31.Park DW, Park SH, Hwang SK. Serial measurement of S100B and NSE in pediatric traumatic brain injury[J]. Childs Nerv Syst, 2019, 35(2): 343-348. DOI: 10.1007/s00381-018-3955-y.

32.李青文, 何志伟, 许红波, 等. 急性前循环供血区脑梗死患者血清NSE及S100B水平变化及其对预后的评估价值[J]. 卒中与神经疾病, 2023, 30(5): 492-496, 513. [Li QW, He ZW, Xu HB, et al. Changes in serum NSE and S100B levels in patients with acute anterior circulation blood supply area cerebral infarction and their evaluation value for prognosis[J]. Stroke and Neurology, 2023, 30(5): 492-496, 513.] DOI: 10.3969/j. issn.1007-0478.2023.05.011.

Popular papers
Last 6 months